Final OS data from the phase III CONTACT-02 trial at ESMO24

ESMO (European Society for Medical Oncology) shared a post on LinkedIn:

”Final OS data from the phase III CONTACT-02 trial in metastatic castration-resistant prostate cancer (mCRPC) did not achieve statistical significance, although a survival advantage was observed with cabozantinib plus atezolizumab in patients with liver or bone metastasis. The final OS analysis in patients who progressed on a first novel hormonal therapy (NHT) was reported at ESMO24. Elena Castro says the combination is unlikely to become standard of care for all patients with mCRPC after progression on NHT, but may be a good option in select cases.

Read the full news on the ESMO Daily Reporter.”

Source: ESMO/LinkedIn

ESMO (European Society for Medical Oncology) represents over 35,000 oncology professionals across 172 countries and is a key resource for oncology education and information. ESMO’s primary mission is to enhance the quality of cancer care, spanning prevention, diagnosis, palliative care, and patient follow-up. It focuses on educating doctors, cancer patients, and the general public about best practices and the latest advancements in oncology, and advocates for equal access to optimal cancer care for all patients.